EANS-Adhoc: Sartorius AG / Order intake and sales revenue substantially increased for both divisions | Positive earnings contributed by the Mechatronics Division | Group operating earnings jumped nearly 50% | Expectations for 2010 confirmed

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

23.07.2010

In the first half of 2010, order intake for the Sartorius Group climbed 9.8%
(currency-adjusted: +8.4%) from EUR306.4 million to EUR336.4 million. Sales
revenue rose 6.3% (currency-adj.: +5.1%) to EUR315.2 million from EUR296.5
million a year ago. The Biotechnology Division received orders valued at
EUR221.4 million, up from EUR203.5 million in the previous year, a plus of 8.8%
(currency-adj.: +7.4%), and increased its sales revenue 5.7% (currency-adj.:
+4.6%) to EUR209.1 from EUR197.8 million a year earlier. The Mechatronics
Division posted a significant gain in order intake of 11.8% (currency-adj.:
+10.4%) to EUR115.1 million from EUR102.9 million in the previous year; its
sales revenue grew 7.5% (currency-adj.: +6.1%) to EUR106.1 million, up from
EUR98.7 million a year ago.

Consolidated earnings before interest, taxes and amortization and adjusted for
extraordinary expenses of EUR1.9 million (prev. year: EUR16.3 mn) — underlying
EBITA — surged 47.0% to EUR36.3 million, up from EUR24.7 million a year earlier;
the respective margin rose from 8.3% to 11.5%. The Biotechnology Division
contributed an underlying EBITA of EUR31.5 million, up from EUR28.0 million a
year ago, which means its margin increased from 14.2% to 15.0%. After posting a
loss of EUR3.4 million in the year-earlier period, the Mechatronics Division
contributed a positive result to Group earnings, reporting an underlying EBITA
of EUR4.8 million and improving its profit margin from -3.4% to 4.5%.

Excluding non-cash amortization, underlying net profit after minority interest
for the first half totals EUR15.9 million (prev. year: EUR6.4 mn); the
respective earnings per share are at EUR0.93, up from EUR0.37 a year ago.

The results achieved meet our expectations for both divisions and confirm our
outlook for the current fiscal year. This outlook forecasts sales growth of
slightly above 5% in constant currencies and further improvement of the
operating EBITA margin by one to two percentage points as well as a
significantly positive operating cash flow.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will
discuss the results with analysts and investors on Monday, July 26, at 4:00 p.m.
Central European Time in a webcast teleconference. You may dial into the
teleconference starting at 3:45 p.m. CET at the following numbers: Germany +49
(0)69 2222 2245; France +33 (0)1 70 99 42 73; UK +44 (0)20 7138 0824; USA +1 212
444 0481
The dial-in code is as follows: 4383672
The webcast and presentation can be viewed at www.sartorius.com.

Further inquiry note:
Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: [email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer:   Sartorius AG
          Weender Landstr. 94-108
          D-37075 Göttingen
phone:    +49 (0)551 308-0
FAX:      +49 (0)551 308-3289
mail:     [email protected]
WWW:      http://www.sartorius.com
sector:   Biotechnology

ISIN: DE0007165607, DE0007165631
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print